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Purpose: To investigate whether initial valproate (VPA) monotherapy for the treat-
ment of epilepsy causes visual field defects and visual dysfunction.
Methods: In a cross-sectional study, visual fields were examined with the kinetic
Goldmann and automated Humphrey perimeters, contrast sensitivity function with
the Pelli—Robson letter chart and colour vision with the Standard Pseudoisochromatic
Plates Part 2 (SPP2) and Farnsworth—Munsell 100 Hue test (FM100) in eighteen
epilepsy patients (aged 18—50 years, 30.2.  10 years, mean  S.D.) treated with
initial valproate monotherapy for 2—20 years (8.4  5.1 years).
Results: None had vigabatrin-type, concentric visual field defect with the kinetic
Goldmann or automated Humphrey perimetries. In the Humphrey perimetry, the
mean deviation for the group was within normal limits varying from 2.53 to 0.59 dB
(0.74  0.80 dB) in the right eye and from2.66 to 0.67 dB (0.78  0.82 dB) in the
left eye.
In the FM100 test, acquired colour vision deficiency was found in two out of 18
patients (11%, 95% CI: 0—25%). However, the mean total error score was lower in the
patient group than in the control group. All patients had normal contrast sensitivity
function.
Conclusions: The use of VPA in the treatment of epilepsy is not associated with visual
field defects similar to vigabatrin, but may induce abnormalities in colour vision.
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Valproate (VPA), is a drug of choice for patients with
partial seizures with or without secondary general-
ization and it is also one of the most effectiveby Elsevier Ltd. All rights reserved.
368 I. Sorri et al.antiepileptic drugs (AED) against generalized
absence seizures.1 Although the precisemechanisms
of action of VPA is not well established, it is
accepted that the drug affects the GABAergic sys-
tem, resulting in elevated GABA levels in central
nervous system.1 GABAergic properties of VPA are
involved in several pharmacodynamic effects of the
drug including possible slight inhibition of GABA
transaminase. Visual field constriction has been
reported in epilepsy patients treated with a
GABAergic AED, vigabatrin (VGB), an irreversible
inhibitor of GABA transaminase.2—4 A combination
therapy with VGB and VPA in the treatment of
epilepsy has been suggested to possess an increased
risk for visual field loss.3,4 However, visual field
defects or electrophysiological abnormalities were
not found in 32 epilepsy patients on VPA monother-
apy,5 but acquired colour vision defects have been
reported in association with VPA therapy.6,7
The concern arising from VGB-associated visual
field defects prompted us to investigate the effects
of VPA on visual function in epilepsy patients treated
with initial VPA monotherapy.Methods
This study was reviewed and accepted by the Ethics
Committee of Kuopio University Hospital and the
University of Kuopio, and was performed in accor-
dance with the ethical standards of the 1964
Declaration of Helsinki. All patients gave written
informed consent.
Eighteen epilepsy patients (eight men, ten
women) with initial VPA monotherapy participated
in this cross-sectional study. The patients suffered
from partial epilepsy with or without secondary
generalisation (N = 8), from juvenile myoclonus epi-
lepsy (N = 4) or other generalized tonic—clonic sei-
zures (N = 6). All except one had VPA as their initial
treatment; one patient had started on carbamaze-
pine but had developed a hypersensitivity reaction
and the therapy was soon switched to VPA. The
patients had normal or mildly subnormal general
intelligence and had been seizure free for several
years. At the time of the epilepsy diagnosis, brain CT
or MRI scans have been performed without findings
that might interfere with visual fields.
A standard ophthalmologic examination including
dilated indirect ophthalmoscopy and measurement
of intraocular pressure with the Goldmann applana-
tion tonometry was performed to exclude eye dis-
eases. The peripheral visual field was examined with
the kinetic Goldmann perimeter (Haag-Streit, Bern,
Switzerland) using stimuli IV/4 and I/3. The central
308 field was examined with the automated staticHumphrey Field Analyzer 750 (HFA, Humphrey Sys-
tems, Dublin, CA) using the 30-2 SITA Standard
threshold strategy. The patient reliability was eval-
uated using the reliability indices of the HFA (<20%
of fixation losses and <33% false positive and nega-
tive answers were accepted).
Colour vision was tested monocularly with two
methods. To exclude congenital red—green colour
vision defects, the Standard Pseudoisochromatic
Plates Part 2 (SPP2) screening test8 was performed
prior to the Farnsworth—Munsell 100 Hue test
(FM100).9 The illumination was provided by a Mac-
beth Easel lamp, 1000 lx, and a near vision correc-
tion was used if needed. The error scores were
calculated as square roots,10 and the axis according
to Smith et al.11 The normal values by Ma¨ntyja¨rvi12
were used in assessing individual results.
Photopic contrast sensitivity was measured with
the Pelli—Robson letter chart, which is designed to
the measurement of mid- to low-spatial frequen-
cies. Normal values of Ma¨ntyja¨rvi and Laitinen13
were used in assessment of individual contrast sen-
sitivity results.
Seventeen healthy volunteers (aged 23—74 years,
43.5  15.2 years) served as controls in the kinetic
visual field evaluation, 47 healthy volunteers (aged
16—55 years, 29.4  11.0 years) in the colour vision
evaluation and 82 healthy volunteers (aged 6—75
years, 34.8  20.8 years) in the contrast sensitivity
evaluation.
Statistical analysis was performed with the SPSS/
PC program (SPSS Inc., Chicago, IL). A p value of
<0.05 was considered significant.Results
The ages of the patients varied from 18 to 50 years
(30.2  10 years). The ages of the patients and con-
trols did not differ in contrast sensitivity and colour
vision comparisons, whereas the control group in the
visual field evaluation was older than the VPA group
(p = 0.004) due to previously collectedmaterial. The
daily dose of VPA varied from 800 to 2000 mg
(1156  307 mg), the duration of therapy from 24
to 240 months (101  61months) and the cumulative
dose from 720 to 9120 g (3580  2309 g). The plasma
concentrations of VPA varied from 171 to 787 mmol/l
(439  154 mmol/l). The best-corrected visual
acuity was 20/25 or better in all eyes.
All kinetic visual fields of the VPA monotherapy
patients were assessed clinically as normal.2 A com-
parison of visual field extents between the patients
and controls is presented in Table 1.
In the automated static perimetry, the reliability
indices were within generally accepted ranges. The
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Table 1 Comparison of kinetic visual field results
(extents of four meridians in degrees) of epilepsy
patients treated with valproate (VPA) and normal con-
trols.




Temporal 92.3  3.4 89.3  2.7 0.008
Range 85—95 82—92
Nasal 57.1  3.3 55.9  4.4 0.352
Range 46—60 45—64
Superior 50.1  4.9 52.9  4.6 0.081
Range 40—58 46—60
Inferior 68.9  4.6 70.8  2.3 0.156
Range 62—75 65—75
Left eye
Temporal 90.8  3.2 88.9  3.3 0.082
Range 82—95 77—92
Nasal 57.2  3.9 58.5  2.8 0.244
Range 48—63 53—62
Superior 48.9  4.8 53.2  4.1 0.008
Range 40—55 45—60
Inferior 67.1  6.0 71.6  2.4 0.007
Range 52—78 66—75
p-value with the Student t-test.mean deviation varied from 2.53 to 0.59 dB
(0.74  0.80 dB) in the right eye and from 2.66
to 0.67 dB (0.78  0.82 dB) in the left eye (Fig. 1).
The pattern standard deviation varied from 1.24 to
2.52 dB (1.78  0.37 dB) in the right eye and from
1.25 to 2.44 dB (1.66  0.30 dB) in the left eye. The
probability analysis of the HFA showed no points or
clusters of p < 0.01 or <0.005 in the edges of 308
visual field indicating an absence of VGB-typed
visual field defect.2
All patients passed the SPP 2 test. Altogether, two
patients of 18 (11%, 95% CI 0—25%) had blue axes in
the FM 100 test in one or both eyes. The total errorFigure 1 The percentage of the eyes according to the
mean deviation (M.D.) in the Humphrey field analyzer
(OD = right eye, OS = left eye).score was within the normal age-dependent
ranges12 in all patients. As a group, a significant
difference was found between the VPA patients and
controls (t-test, p = 0.004 in the right and p = 0.001
in the left eye), but surprisingly, the error scores
were significantly lower in the patient group (right
eye: 6.1  2.6; left eye: 6.1  2.7) than in the
control group (right eye: 8.3  2.6; left eye
8.4  2.4). No correlation was found between the
FM100 error scores and the duration of VPA therapy,
the cumulative dose of VPA or the plasma concen-
trations of VPA.
Individual contrast sensitivity values were within
normal limits.13 As a group, the results between
patients (right eye: 1.78  0.1, range 1.65—1.95;
left eye: 1.78  0.1, range 1.65—1.95) and controls
(right eye: 1.77  0.1, range 1.5—1.95; left eye:
1.76  0.1, range 1.65—1.95) did not differ.Discussion
The results of the present study indicate that the
use of VPAmonotherapy in the treatment of epilepsy
is not associated with visual field defects. This is in
concordance with the previous study in epilepsy
patients receiving long-term VPA monotherapy.5
The characteristics of VGB-associated visual field
defects have been established in several stu-
dies.2—4 In the present study, both kinetic and auto-
mated static perimetries were performed to
accurately find any visual field defects. Typical
concentric or annular nasal visual field defects were
not found by either method. On the contrary, VPA
patients showed even wider kinetic fields than nor-
mal controls in some meridians. However, the VPA
monotherapy patients were younger than the con-
trols.
Our results confirm previous findings that VGB-
associated visual field defects seem not to be a
class—effect of GABAergic AEDs but VGB-specific
phenomena. This opinion is supported also by two
studies in which tiagabine, the anticonvulsant
mechanism of which resembles most of all AEDs
to that of VGB, has not been shown to cause visual
field defects.14,15
On the basis of the GABAergic properties of VPA,
it has been discussed that combination therapy with
VGB and VPA might be particularly retinotoxic.3,4
The GABAergic properties of VPA are only a part of
its mode of action, and it is unclear if and how VPA
increases retinal toxicity of VGB. Accumulation of
VGB and GABA in the retina has been suggested to be
the mechanism of VGB retinotoxicity16 but still, the
exact mechanism has not been elucidated. In
rodents, after administration of VPA, inhibition of
370 I. Sorri et al.nerve-terminal GABA-transaminase and increase in
presynaptic GABA has been observed.1 An additive
inhibitory effect of VPA on GABA transaminase might
be one explanation.
In the present study, contrast sensitivity tests did
not reveal any abnormalities but, minor abnormal-
ities in colour vision were found in two patients. In
newly diagnosed epilepsy patients treated with VPA
or carbamazepine for 1 year, a clear decline in both
central and paracentral colour vision examined with
the FM100 and Short Wavelength Automated Peri-
metry (SWAP) was reported.6 This may indicate
general retinotoxicity related to the use of AEDs,
but affecting mainly short wavelength sensitive
cones.7 Nevertheless, the colour vision deficit asso-
ciated with the use of VPA is mostly subclinical, does
not affect visual performance in the everyday life of
epilepsy patients and therefore does not require
monitoring.Acknowledgement
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